O'Donnell MA - Search Results

1

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF. Dinney CP, et al. J Urol. 2013 Sep;190(3):850-6. doi: 10.1016/j.juro.2013.03.030. Epub 2013 Mar 15. J Urol. 2013. PMID: 23507396 Free PMC article. Clinical Trial.

2

Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B.

Downs TM, Szilvasi A, O'Donnell MA. Downs TM, et al. J Urol. 1997 Dec;158(6):2311-5. doi: 10.1016/s0022-5347(01)68241-7. J Urol. 1997. PMID: 9366382

3

Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.

Jackson AM, Ivshina AV, Senko O, Kuznetsova A, Sundan A, O'Donnell MA, Clinton S, Alexandroff AB, Selby PJ, James K, Kuznetsov VA. Jackson AM, et al. J Urol. 1998 Mar;159(3):1054-63. J Urol. 1998. PMID: 9474231

4

Superficial bladder cancer: the role of interferon-alpha.

Belldegrun AS, Franklin JR, O'Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL, Williams RD. Belldegrun AS, et al. J Urol. 1998 Jun;159(6):1793-801. doi: 10.1016/S0022-5347(01)63160-4. J Urol. 1998. PMID: 9598463 Review.

5

Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.

Poppas DP, Pavlovich CP, Folkman J, Voest EE, Chen X, Luster AD, O'Donnell MA. Poppas DP, et al. Urology. 1998 Aug;52(2):268-75; discussion 275-6. Urology. 1998. PMID: 9697793

6

Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.

Luo Y, Chen X, Han R, Chorev M, Dewolf WC, O'Donnell MA. Luo Y, et al. J Urol. 1999 Oct;162(4):1519-26. J Urol. 1999. PMID: 10492248

7

Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.

O'Donnell MA, Krohn J, DeWolf WC. O'Donnell MA, et al. J Urol. 2001 Oct;166(4):1300-4, discussion 1304-5. J Urol. 2001. PMID: 11547062

8

Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base.

Konety BR, Joslyn SA, O'Donnell MA. Konety BR, et al. J Urol. 2003 Mar;169(3):946-50. doi: 10.1097/01.ju.0000052721.61645.a3. J Urol. 2003. PMID: 12576819

9

Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis.

Joudi FN, Smith BJ, O'Donnell MA, Konety BR. Joudi FN, et al. Urology. 2003 Dec;62(6):1083-8. doi: 10.1016/s0090-4295(03)00765-9. Urology. 2003. PMID: 14665360

10

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.

Lam JS, Benson MC, O'Donnell MA, Sawczuk A, Gavazzi A, Wechsler MH, Sawczuk IS. Lam JS, et al. Urol Oncol. 2003 Sep-Oct;21(5):354-60. doi: 10.1016/s1078-1439(03)00012-7. Urol Oncol. 2003. PMID: 14670544

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

252 results

Search Page

Filters